GlassScriptPhysician profile
Aamir Hussain
NPI 1861729170
$2,371.68
in general payments reported to CMS, 2019-2025
38 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $34.17 · 2021: $351 · 2022: $156 · 2023: $533 · 2024: $987 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.03 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.25 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $206.32 | 2021-2024 | Tagrisso, Lynparza |
| Sanofi-Aventis U.S. LLC | $195.90 | 2022-2025 | |
| Janssen Biotech, INC. | $182.57 | 2021-2024 | Erleada, Darzalex, Talvey |
| Genzyme Corporation | $136.60 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $116.36 | 2021-2024 | Keytruda, Lynparza |
| Celgene Corporation | $108.82 | 2023-2024 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $104.67 | 2023-2024 | Opdivo |
| Sobi, INC | $86.60 | 2023-2024 | |
| Eisai INC. | $78.29 | 2024 | |
| Amneal Pharmaceuticals LLC | $77.35 | 2023-2024 | Avastin, Neupogen, Neulasta |
| Astellas Pharma US INC | $72.18 | 2021-2024 | Xtandi, Xospata |
| Ucb, INC. | $70.77 | 2019 | |
| Abiomed | $66.04 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $48.59 | 2023-2024 | Somatuline Depot, Onivyde, Tazverik |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $45.87 | 2024 | Prolaris |
| Abbvie INC. | $41.66 | 2024 | |
| Beigene USA, INC. | $39.11 | 2024 | Brukinsa |
| Dova Pharmaceuticals | $35.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.98 | 2023-2024 | Xarelto |
| Seagen INC. | $32.43 | 2023 | Padcev |
| Recordati_rare_diseases_inc. | $32.18 | 2024 | Sylvant |
| Abbott Laboratories | $30.16 | 2019 | |
| Telix Pharmaceuticals | $28.38 | 2025 | Illuccix |
| Pharmacosmos Therapeutics INC. | $25.34 | 2024 | Monoferric |
| Array Biopharma INC | $24.55 | 2024 | Braftovi, Lorbrena, Mektovi |
| Incyte Corporation | $22.84 | 2020-2021 | |
| Amgen INC. | $20.32 | 2023 | Kyprolis, Blincyto |
| Boston Scientific Corporation | $19.99 | 2025 | Spaceoar System |
| Emd Serono, INC. | $19.58 | 2023 | Bavencio |
| Exelixis INC. | $18.64 | 2024 | Cabometyx |
| G1 Therapeutics, INC. | $16.50 | 2022 | |
| Daiichi Sankyo INC. | $13.02 | 2021 | |
| Glaxosmithkline, LLC. | $12.85 | 2021 | |
| Servier Pharmaceuticals LLC | $12.65 | 2022 | |
| Puma Biotechnology, INC. | $12.15 | 2021 | |
| Global Blood Therapeutics, INC. | $11.81 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.